Adiponectin: A relevant player in PPARγ-agonist-mediated improvements in hepatic insulin sensitivity?

M. Bouskila, U. B. Pajvani, P. E. Scherer

Research output: Contribution to journalArticlepeer-review

141 Scopus citations


The potent insulin-sensitizing effects of peroxisome proliferator-activated receptor γ (PPARγ) agonists are well established. However, it is still a matter of intense debate as to which tissue(s) represent the most critical sites of action for PPARγ agonists, and what the relevant target genes are that ultimately mediate the improvements in insulin sensitivity. The cell type with the highest levels of PPARγ is the adipocyte, and as such the adipocyte is an excellent candidate cell to look for critical mediators of PPARγ agonist action. Adiponectin, an adipocyte-specific secretory protein, is upregulated in response to PPARγ agonist exposure, and its serum levels consequently increase significantly. Genetic, pharmacological and clinical studies have demonstrated potent insulin-sensitizing effects of adiponectin. Here, we summarize the evidence that implicates adiponectin as a critical mediator of PPARγ-agonist-mediated improvements in insulin sensitivity, particularly in the context of PPARγ-agonist-mediated enhancements of hepatic insulin sensitivity.

Original languageEnglish (US)
Pages (from-to)S17-S23
JournalInternational Journal of Obesity
StatePublished - 2005


  • Acrp30
  • Gluconeogenesis
  • Rosiglitazone

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics


Dive into the research topics of 'Adiponectin: A relevant player in PPARγ-agonist-mediated improvements in hepatic insulin sensitivity?'. Together they form a unique fingerprint.

Cite this